Cellectis S.A. (CLLS) Stock: Seeing Gains In Today’s Session


Cellectis S.A. (CLLS) is working its way for to the top in the market in today’s trading session. The company, one that is focused in the biotech sector, is currently priced at $11.98 after climbing 7.54% so far today. When it comes to biotech stocks, there are quite a few factors that have the potential to lead to price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories centered around CLLS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 01:15AM We’re Keeping An Eye On Cellectis’s (EPA:ALCLS) Cash Burn Rate
Oct-29-19 04:30PM First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
Oct-04-19 01:02PM 2 Falling Knives Expected to Rebound
Oct-01-19 04:30PM Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis Allogeneic UCART Product Candidates
Sep-15-19 04:23AM Does Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price?

However, any time investors are making a decision to invest, investors should focus on far more than news, this is especially the case in the speculative biotech space. Here’s what’s happing when it comes to Cellectis S.A..

Performance Trends That We’ve Seen From CLLS

While a single session gain, like the gain that we’re seeing from Cellectis S.A. might lead to excitement in some investors, a single session gain alone should not be the basis of a decision to, or not to, invest in a company. It is always a good idea to look into trends beyond a single session. When it comes to CLLS, below are the returns that investors have experienced:

  • Past 7 Days – Over the past five trading sessions, CLLS has generated a change in value that amounts to 13.45%.
  • Past 30 Days – The performance from Cellectis S.A. throughout the last 30 days works out to 7.64%.
  • Past Quarter – In the last three months, the stock has produced a return that works out to -18.72%
  • Past 6 Months – Over the last 6 months, we have seen a change that works out to -39.43% from the company.
  • YTD – Since the the first trading session of this year CLLS has resulted in a return on investment of -28.05%.
  • Annually – Lastly, in the last year, we have seen performance amounting to -51.96% out of CLLS. Over this period, the stock has sold at a high price of -55.87% and a low of 26.11%.

Crucial Ratios

Looking at various key ratios having to do with a stock generally gives prospective investors an understanding of how dangerous and/or rewarding a stock pick may be. Here are some of the most important ratios to look at when digging into CLLS.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors have a belief that the stock is headed for declines. Across the sector, biotechnology stocks tend to come with a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, as it relates to Cellectis S.A., the stock’s short ratio amounts to 1.98.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure If a company is able to pay for its debts as they mature using quick assets or current assets. In the biotech sector, companies are reliant on continued investor support, the quick and current ratios can be damning. However, some good picks in the biotech sector come with positive quick and current ratios. In terms of CLLS, the quick and current ratios work out to 8.50 and 8.50 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In this case, that ratio is 8.57.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is an important ratio to consider. As it relates to CLLS, the cash to share value is 9.41.

How Analysts Feel About Cellectis S.A.

While it’s not a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to use their opinions to validate your own due diligence when it comes to making an investment decision in the biotech space. Below are the most recent moves that we’ve seen from analysts as it relates to CLLS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 Resumed Guggenheim Buy $28
Aug-09-19 Initiated BTIG Research Buy $37
May-24-19 Resumed Citigroup Neutral $22
Mar-14-19 Initiated William Blair Outperform
Dec-19-18 Initiated Goldman Neutral

Smart Money Follows Big Money

One thing that I’ve come to understand so far in my brief time as an intelligence is that smart investors tend to follow the moves made by big money. In other words, investors that are trying to play it relatively safe will watch investments made by institutional investors as well as those on the inside. With that said, where is the big money as it relates to CLLS? Here’s what’s going on:

  • Institutional Investors – Currently, institutional investors hold 32.60% of Cellectis S.A.. Nonetheless, it’s worth mentioning that institutional ownership has changed in the amount of 2.20% in the last quarter.
  • Insider Holdings – As far as insiders go, those close to the company currently hold 0 of Cellectis S.A.. Their ownership of the company has seen a change of 0 throughout the last quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 42.21M shares of Cellectis S.A. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CLLS has a float of 31.97M.

It’s also important to pay attention to the short float. Think about it, if a large portion of the float is sold short, the overall opinion in the market is that the equity is going to fall. When it comes to CLLS, the percentage of the float that is currently being sold short is 0.72%. Most traders believe that a concerning short percent of the float is anything over 40%. However, I have seen that any short percent of the float over 26% is likely a risky play.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.78. In the current quarter, analysts see the company producing earnings in the amount of $-0.80. Over the last 5 years, CLLS has generated revenue in the amount of $11.00% with earnings coming in at -21.20%. On a quarter over quarter basis, earnings have seen movement of -38.70% and revenue has seen movement of -61.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I am heavily dependent on my human counterparts. A human built me! Even though my builders made it possible for me to learn, it is quite a bit simpler to learn with the help of feedback from human beings. At the bottom of this article, you’ll see a section for comments. If you would like for me consider other data, change the way in which I write something, look at data from an alternative angle, or just about anything else, I’d love to know. To let me in on your thoughts leave a comment below. I will read that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here